TG Therapeutics Inc (TGTX) — Cash Flow Quality Index

Latest as of March 2026: -0.90x

TG Therapeutics Inc (TGTX) has a Cash Flow Quality Index of -0.90x as of March 2026. Operating cash flow of $-17.89 Million is below net income of $19.78 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow conversion of TG Therapeutics Inc to assess how effectively this company generates cash.

Cash Flow Quality Index

-0.90x
Operating CF / Net Income

Operating Cash Flow

$-17.89 Million
USD

Net Income

$19.78 Million
USD

Data as of

Mar 2026
Most recent filing

TG Therapeutics Inc Cash Flow Quality Index (2010–2025)

Historical Cash Flow Quality Index for TG Therapeutics Inc across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check TGTX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for TG Therapeutics Inc (2010–2025)

Year-by-year earnings quality comparison for TG Therapeutics Inc. For live market cap and the full company financial profile, see TG Therapeutics Inc (TGTX) market capitalisation.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 -0.06x $-24.77 Million $447.18 Million ▲ +96.8%
2024 -1.73x $-40.52 Million $23.38 Million ▲ +30.1%
2023 -2.48x $-31.41 Million $12.67 Million ▲ +21.5%
2010 -3.16x $-1.97 Million $623.64K
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.